Form 4: TG Therapeutics Director Kenneth Hoberman Reports Acquisition of 22,250 Shares

Director Kenneth Hoberman reports acquiring 22,250 shares of TG Therapeutics common stock through a grant of restricted shares.

Summary

• On June 19, 2024, Kenneth Hoberman, a director of TG Therapeutics, Inc., acquired 22,250 shares of common stock.
• The acquisition was a grant of restricted shares.
• These restricted shares will vest on June 14, 2025.
• Following the transaction, Hoberman beneficially owns 264,935 shares of TG Therapeutics, Inc., including restricted common stock that vests over various time periods.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock acquisition by a director. While insider buying can be seen as positive, this is a grant of restricted shares, which is part of standard compensation.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide investors with insights into the actions of company insiders, such as directors and officers.

Stakeholder Impact

• The acquisition of shares by a director may have a slightly positive impact on shareholder sentiment.

Key Dates